Abstract-Bioresorbable lms can serve simultaneously as anatomic support structures and as drug delivery platforms. In the present study, bioresorbable poly(L-lactic acid) (PLLA) lms containing dexamethasone were prepared by solution processing methods. Their in vitro studies focused on the mechanical properties with respect to morphology and degradation and erosion processes. Novel expandable support devices (stents) developed from these lms were studied. Such a stent would support conduits, such as the neonatal trachea to treat tracheal malacia, until the airway matures, and would then be totally resorbed, obviating the need for a removal operation. The PLLA lms showed good initial mechanical properties. They can accommodate drug incorporation on the lm surface and also in the bulk. Water incubation of the lms results in a decrease in their tensile mechanical properties, due to chain scission and morphological changes. These changes can vary from degradation and small changes in morphological features to erosion, leading to a microporous structure, depending on the polymer. The cumulative release of dexamethasone from the lms is linear. The rate of release is determined by the lm's structure (drug location/ dispersion). The stents demonstrated good mechanical properties. The initial radial compression strength of the stent is determined mainly by the polymer structure. Drug incorporation has a minor effect on the initial stent strength. Exposure to radial compression stress results in elastic reversible deformation or a sudden brittle fracture, depending on the polymer. A 20-week in vitro study of the stents showed that they are applicable for supporting body conduits, such as the trachea.
INTRODUCTION
Poly(lactic acid) (PLA) is one of the most important biodegradable polymers and is used in a wide range of clinical applications, such as devices for orthopedic surgery [1 -3] , cardiovascular surgery [4] , sutures [5] , and as drug-delivering implants [6, 7] . The semi-crystalline poly(L-lactic acid) (PLLA) is well known for the rst three applications mentioned, where high mechanical strength and toughness are required. This polymer can be formed into lms, tubes, and matrices using standard processing techniques such as molding, extrusion, solvent casting, and spinning [5] .
The metal stents currently used for blood vessel support can also serve for airway support [8 -10] . However, an ideal bioresorbable tracheal stent would support the neonatal trachea in tracheal malacia, until the airway matures, and would then be totally resorbed, obviating the need for a removal operation. Several bioresorbable stents for various applications have been reported [11] [12] [13] . Ye et al. [11] developed a tubular PLLA/polycaprolactone microporous stent for delivering gene transfer vectors to the arterial wall. Kemppainen et al. [12] reported a spiral PLLA stent and Brauers et al. [13] described tubular poly(DL-lactic acid) and poly(DL-lacticco-glycolic acid) stents, both for urethral applications. None of these stents is expandable. We have developed a novel expandable stent, prepared from a solutioncast PLLA-based lm. Dexamethasone, a steroidal anti-in ammatory drug, is incorporated into this lm-based stent to provide controlled local release of the drug during the mechanical support phase. In addition to its well-known antiin ammatory activity, dexamethasone has been demonstrated to inhibit brotic response. The addition of this drug may therefore be helpful in the prevention of proliferative reactions, such as airway stenosis. This support structure was tested in vivo as a tracheal stent, to support the tracheal airway and to treat tracheomalacia.
One of our recently reported studies focused on bioresorbable PLA lms containing dexamethasone, prepared through solution processing [14] . The effect of processing parameters and components on the lm morphology was studied and a model describing the structuring of these lms was suggested. In general, the solvent evaporation rate determines the kinetics of drug and polymer crystallization, and thus the mode of drug dispersion in the lm, while the polymer chain structure and its morphology have a minor effect on the drug distribution. Polymer/ dexamethasone lms were reported in this paper for the rst time.
The present paper reports the results of a 20-week in vitro study of PLLA /dexamethasone lms and the support devices (stents) prepared from these lms. The study focused on the mechanical properties of the lms and the devices. The morphology, degradation, and erosion processes and the polymer's initial molecular weight have signi cant effects on the resulting properties. 
EXPERIMENTAL

Materials
High-molecular-weight poly(L-lactide) (H-PLLA), RESOMER L21 (i.v. D 3:6 dl/ g in CHCl 3 at 30 ± C), was from Boehringer Ingelheim, Germany; low-molecularweight poly(L-lactide) (L-PLLA), L-PLA (i.v. D 1:02 dl/g in CHCl 3 at 30 ± C), was from Birmingham Polymers, USA; and dexamethasone (DM) USP (®-uoro-162-methylprednisolone SIGMA D-9184) was from Sigma.
Film preparation
Polymer lms (0.12-0.15 mm in thickness) consisting of poly(lactic acid) (98 wt%) and dexamethasone (2 wt%) were prepared by a three-step solution processing method:
(a) Components were mixed in chloroform at room temperature until the polymer dissolved. The solubility of DM in chloroform at room temperature is approximately 1 mg/ml. Its solubility in water is 0.1 mg /ml [15] . A dilute solution was prepared by using a relatively large volume of chloroform (concentration range of the polymer: 0.01-0.02 g/ml; concentration range of DM: 2 £ 10 ¡4 -10 ¡3 g/ ml). Both DM and poly(lactic acid) were totally dissolved. A concentrated solution was prepared by using a relatively small volume of chloroform (concentration range of the polymer: 0.05-0.1 g/ ml; concentration range of DM: 10 ¡3 -5 £ 10 ¡3 g/ml). In this solution the polymer was totally dissolved, while the DM powder was only broken into small particles (aggregates), which yielded an opaque solution. (b) Solution casting into a Petri dish and solvent drying under atmospheric pressure at room temperature. (c) Isothermal heat treatment at 90 ± C for 1 h in a vacuum oven.
Stent preparation
Polymer/ DM lms were prepared as described above in steps (a) and (b). They were rolled onto a cylindrical mandrel, annealed at 90 ± C for 1 h in a vacuum oven while on the mandrel, and then removed from the mandrel.
Measurements of the mechanical properties
The mechanical properties of the lms were measured at room temperature in unidirectional tension at a rate of 10 mm /min (ASTM D 882-97), using a Universal Testing System machine (MTS Systems Corporation, Eden Prairie, MN, USA). The tensile strength was de ned as the maximum strength in the stress -strain curve; the maximal strain as the breaking strain; and Young's modulus as the slope of the stress-strain curve in the elastic (linear) region. The radial compression strength of the stents was measured by a special chamber, constructed in our laboratory. This chamber, described in Fig. 1 , permits hydrostatic pressure to be applied to the external surface of the stent. A dilated stent is located on a rubber tip and a small plastic bag, placed over it, is closed airtight with wire. The chamber is ported to a manual air pump for pressurization and a sphygmomanometer is used to measure the pressure in the chamber. The pressure difference across the stent wall is increased gradually and the resulting change in the stent diameter is measured.
Five samples were tested for each point, for both mechanical property measurements. The mean values and standard deviations are presented in the graphs.
Morphological characterization
Polarized light microscopy (LM) was carried out using an Olympus BHS compound microscope. Scanning electron microscopy (SEM) of cryogenically fractured surfaces was performed using a JEOL JSM 840 A at an accelerating voltage of 5 kV. The SEM samples were Au/Pd-sputtered prior to observation. High-resolution scanning electron microscopy (HRSEM) of cryogenically fractured surfaces was carried out using a Leo Gemini-982 at an accelerating voltage of 1 kV.
In vitro degradation studies
To determine the degradation rate, lms were weighed and then oated on sterile water (50 ml, in a Petri dish) at 37 ± C. One side of the lm was exposed to water and the other side to water-saturated air, to simulate the conditions in the trachea. Every 2 weeks, samples were taken out, dried in a vacuum oven, and weighed. The 
where w 0 and w f are the weights of the dried lms before and after water exposure, respectively. Five samples were tested for each point. The mean values and standard deviations are presented in the graphs.
To determine the degradation of tensile mechanical properties, lm samples were also oated on sterile water at 37 ± C for certain periods of times and then removed, dried, and tested as described in the section on the measurements of the mechanical properties. In addition, stents formed from lms were immersed in sterile water, as before, and then studied for the degradation in their radial compression strength.
In vitro drug release study
To determine the release kinetics of DM from the lms, the lms were oated on sterile water at 37 ± C. Samples of 1.5 ml were collected periodically and their DM content was measured using high performance liquid chromatography (HPLC) (DX 500; Dionex Corp., Sunnyvale, CA, USA). An AD-20 ultraviolet detector (Dionex Corp.) monitored the absorbance at 254 nm, and the area of each eluted peak was integrated using Peak Net software (Dionex Corp.) and used for quantitative analysis.
RESULTS AND DISCUSSION
PLLA /DM lms
PLLA /DM lms were prepared through solution casting. In this process, the solvent evaporation rate strongly affects the kinetics of drug and polymer crystallization, and thus both the mode of drug dispersion in the polymer and the resulting mechanical properties. Two types of PLLA /DM lm structures were created and studied for both PLLA types, H-PLLA and L-PLLA. They are presented for the H-PLLA lms in Figs 2a and 2b, in comparison with the structure of the neat H-PLLA lm ( Fig. 2c): (a) A polymer lm with large drug tertiary shapes located on its surface, as presented in Fig. 2a . This structure, derived from diluted solution, was obtained due to prior drug nucleation and growth on the polymer solution surface. The skin formation is accompanied by a later polymer core formation. This structure is termed type 'A'. (b) A polymer lm with small drug particles and crystals distributed within the bulk, as presented in Fig. 2b . This structure, derived from concentrated solution, is obtained due to drug nucleation and segregation within a dense polymer solution. Solidi cation of drug and polymer occurred in parallel. The drug is located in amorphous domains of a semi-crystalline matrix, around the spherulites. This structure is termed type 'B'.
We have extensively studied the morphology and formation process of these structures and a model describing the structuring of these lms has been suggested [14] . The tensile mechanical properties of H-PLLA and L-PLLA lms containing DM were studied and compared with those of the neat PLLA lms. The measured maximal tensile strength (at break), elastic modulus, and maximal strain (at break) are presented in Table 1 . Both types of lms, H-PLLA and L-PLLA, are relatively brittle. Their maximal strain at break does not exceed 5.4%. The neat H-PLLA is stronger and tougher than L-PLLA, probably due to the higher molecular weight. Similar tensile mechanical properties for L-PLLA have also been reported in other studies [16, 17] .
In general, the incorporation of DM in H-PLLA or L-PLLA decreases the strength, modulus, and maximal strain (Table 1 ). In the A-type lms, DM is located on the surface of the PLLA matrix and the polymer structure is very similar to that of neat PLLA; the changes in mechanical properties are therefore relatively small. The poor quality of the layers close to the PLLA-DM interphase is probably responsible for these changes. In contrast, in the B-type lms, most of the DM is located within PLLA. As a result, for both H-PLLA and L-PLLA, the deterioration in the mechanical properties due to DM incorporation is more signi cant than in the A-type lms. The DM molecules consist of a four-ring planar structure and could therefore be expected to function as a stiff organic ller, increasing stiffness and strength. However, the completely different nature of these components and the lack of interactions between them contribute to poor interphase adhesion and result in deterioration in the mechanical properties. Interestingly, the deterioration in mechanical properties due to drug incorporation is more signi cant for the L-PLLA lm than for the H-PLLA lm, especially in the B-type lms. One of our previous studies has shown that L-PLLA lms exhibit 53.6% crystallinity, while H-PLLA lms exhibit only 41.4% [14] . Also, the L-PLLA spherulites (20-100 ¹m in diameter) [14] are larger than the H-PLLA ones (less than 10 mm) (Fig. 2c) . It is thus suggested that the relatively large amount of amorphous phase and ner spherulitic structure of H-PLLA can better tolerate drug incorporation than the smaller amount of amorphous phase and coarser structure of L-PLLA.
The PLLA /DM lms were oated on sterile water at 37 ± C in order to investigate the effect of their in vitro degradation on the mechanical properties. The tensile mechanical properties of H-PLLA-based lms as a function of time are presented in Fig. 3 . In general, the tensile strength, modulus, and ductility decrease with the (Fig. 3a) . The strength of the A-type lm is consistently lower than that of the neat H-PLLA lm, probably due to the low mechanical properties of the layers near the polymer/ DM interphase. Interestingly, the tensile strength of the B-type lm also decreases linearly with time, but the slope is smaller than those of the neat H-PLLA and A-type lms. Thus, the incorporation of DM in the lm contributes to better retention of lm strength when exposed to water. Similarly, Young's modulus of the H-PLLA/DM (A) lm is lower than that of the neat H-PLLA lm throughout the 20-week period of study (Fig. 3b ). The modulus of the H-PLLA/DM (B) lm almost does not change during the rst 12 weeks of study and is slightly reduced afterwards. The H-PLLA and H-PLLA/DM (A) lms are more ductile than the H-PLLA/DM (B) lm throughout the 20 weeks of study (Fig. 3c) . However, the latter's ductility almost does not change with time. The decrease in maximal strain is equivalent to the decrease in tensile strength and modulus for the H-PLLA-based lms studied.
A different behavior of the mechanical properties was observed for the L-PLLA lms. The deterioration in their mechanical properties was much faster than that observed for the H-PLLA lms, as demonstrated in Fig. 4a . While the H-PLLA lm lost less than 10% of its initial tensile strength after 4 weeks' otation on sterile water, the L-PLLA lm showed a much greater decrease of approximately 50% in tensile strength. The L-PLLA lm became very brittle and could not be handled after longer periods of otation time.
The lms' weight retention and morphology were studied to elucidate and understand the mechanical property behavior. While the H-PLLA lm retained its initial mass and exhibited a decrease of less than 1% in weight after 20 weeks of degradation, the L-PLLA lm started to lose weight after 2 weeks and exhibited a decrease of approximately 8% after 20 weeks (Fig. 4b) .
SEM micrographs of the cryogenically fractured surfaces of H-PLLA and L-PLLA lms after exposure to water for 20 weeks are presented in Fig. 5 , in comparison with the morphology of the unexposed lms. The characteristic features of the H-PLLA lm after exposure to water for 20 weeks (Fig. 5b ) remained similar to those of the original one (Fig. 5a ), but the topography became rougher. In contrast, signi cant changes in morphology were observed for the L-PLLA lm after exposure to water. Two characteristic textures were observed: a rough fractured surface, typical of an eroded polymer (Fig. 5d) , and a ne microporous structure (0.2-1 ¹m in diameter) (Fig. 5e) . It seems that the former texture is more typical of the lm surface, while the latter is more typical of the interior. These observations are in agreement with those in the literature [18, 19] , which suggest that degradation does not occur homogeneously, but rather more quickly in the interior than on the surface, due to acidic self-catalysis. The process of 'degradation' describes the chain scission process, during which polymer chains are cleaved to form oligomers and nally to form monomers. The 'erosion' process designates the loss of material owing to monomers and oligomers leaving the polymer [20] . The degradation and morphology studies (Figs 4 and 5) demonstrate that during the 20-week study the H-PLLA lms undergo degradation. Their mass remains practically unchanged and the relatively small deterioration in tensile mechanical properties is attributed to (1) chain scission, leading to a decrease in the average molecular weight; and (2) morphological changes. In addition to degradation, the L-PLLA lms undergo erosion, starting after 2 weeks of exposure to an aqueous medium (Fig. 4b) . Their structural changes (Figs 5d and 5e ) enable the release of low-molecular-weight fragments.
The deterioration in the tensile mechanical properties is faster for the L-PLLA lms than for the H-PLLA lms, for the following reasons:
(a) The initial molecular weight of L-PLLA (i.v. D 1:02 dl/ g) is lower than that of H-PLLA (i.v. D 3:6 dl/g). Hence, low-molecular-weight fragments are obtained after a relatively short period of time, giving rise to erosion and pore formation.
(b) The L-PLLA lm is more crystalline than the H-PLLA lm and its spherulites are larger [14] . Hence, its amorphous phase is more susceptible to degradation by simple hydrolysis.
The cumulative DM release pro les from L-PLLA-based lms are presented in Fig. 6 . Both types of lms, A and B, exhibited an almost linear release pro le, i.e. constant release rate (slope). Such systems are desirable for many controlled release applications [21] . While the A-type lm contains large DM crystals on the polymer lm surface, most of the DM in the B-type lm is located in the polymer lm (Fig. 2) . Therefore, as expected, the DM release rate from the A-type lm is faster than from the B-type lm.
During the rst 2 days, DM was probably released only from the lm surface. Therefore, at this early stage, the quantities released from both lms are similar. After 24 weeks, the A-type lm released 82% of its drug and the B-type lm released 45% of its drug. The gradual release of DM from the B-type lm is related to gradual degradation of the polymer and is also determined by the diffusion rate of DM from the lm. The gradual release of DM from the A-type lm is probably related to its poor miscibility in water. A large-scale drug release study will soon be submitted for publication. It includes the release of DM from semi-crystalline polymer lms [polydioxanone, 10/90 poly(DL-lactide-co-glycolide), and PLLA] and also from amorphous ones [50/ 50 poly(DL-lactide-co-glycolide) and 85/15 poly(DL-lactide-co-glycolide)]. The effect of the degradation rate and polymer degree of crystallinity on the release kinetics was studied. A mathematical model was also developed.
Expandable PLLA /DM stents
A novel expandable tubular stent was developed from these lms. The dilated form is presented in Fig. 7a . The thickness of the lm was 0.12-0.15 mm and the length of the stent 15 mm. This device is designed to serve for neonatal airway support and therefore the diameter of the dilated form for the in vitro studies was designed to be 6.0 mm. Holes of 3 mm diameter were created in the lm, to enable removal of contamination from the airway, in the stent vicinity. Schematic representations 
138 § 17 117 § 16 focusing on the cross-sectional shape of the pre-dilated and the dilated stents are presented in Figs 7b and 7c , respectively. The diameter of the dilated stent is determined by the size of the mandrel used for stent preparation (see Experimental section). The nal diameter / initial diameter ratio is adjustable and can reach a maximum of 2.5. For the current in vitro study, a ratio of 2.0 was chosen. The predilated form (Fig. 7b) is obtained when reducing the diameter of the stent by coiling and stabilizing the coiled stent in the coiled position. Releasing the stabilization of the coiled (pre-dilated) stent will allow self-expansion to the nal dilated form (Fig. 7c) .
The initial radial compression properties of H-PLLA and L-PLLA stents formed in this con guration are presented in Table 2 . The maximal applied pressure using our radial compression chamber is 200 kPa; therefore higher strength values could not be measured. In general, the H-PLLA-based stents are stronger than the L-PLLA stents. They can endure a radial compression pressure of at least 200 kPa without exhibiting any deformation. The L-PLLA stents start to deform at 138 kPa and they break at 158 kPa. They exhibit a small elastic deformation before brittle failure. Incorporation of DM in the lm reduces the stent's radial compression strength and it starts to deform at lower pressure. However, both stent types, H-PLLA and L-PLLA, demonstrated initial radial compression strengths at least 50 times higher than the strength required for the tracheal application (approximately 3 kPa). The tensile mechanical properties of a polymer are more sensitive to poor polymer-ller interphase adhesion than compression properties. Therefore the stent's compression strength (Table 2) is less sensitive to drug incorporation than the tensile mechanical properties of the lm ( Table 1) .
The stents were immersed in sterile water at 37 ± C in order to investigate the effect of their in vitro degradation on the mechanical properties. Two modes of failure were obtained, as presented in Fig. 8 . The H-PLLA stents tend to deform in the radial direction and exhibit an elliptical shape. The deformation increased with radial compression pressure, until the stent was almost attened, as shown in Fig. 8b . The stent returned to its original tubular shape after the radial pressure was removed. Hence, the deformation exhibited is elastic. This mode of failure was obtained only for samples that were immersed for more than 10 weeks. In contrast, the L-PLLA stents, prepared from a weaker and more brittle polymer, exhibited a small deformation in the radial direction and then developed a fracture in the longitudinal direction, between two adjacent holes, as shown in Fig. 8c . The stents that were immersed for more than 2 weeks exhibited the described fracture without showing any earlier deformation. Hence, the radial pressure needed in order to start a deformation was considered to be a failure point for the H-PLLA stents and the radial pressure needed to create a fracture was considered to be a failure point for the L-PLLA stents. The latter failure is not desired, since it appears suddenly, without showing any prior signs.
The radial pressure needed in order to start an elastic (reversible) deformation in the radial direction for the H-PLLA stents, as a function of the immersion time, is presented in Fig. 9 . The H-PLLA/DM (B) stent did not show any elastic deformation, after applying 200 kPa, throughout the 20 weeks studied. The radial compression pressure needed to initiate deformation in the neat H-PLLA and H-PLLA/ DM (A) stents was also not lower than 200 kPa for the rst 10 weeks and then showed a linear decrease with time. In general, the H-PLLA stents demonstrated good strength and subsequent ductility. Hence, while becoming weaker, due to further degradation with time, they may not exhibit an unexpected brittle fracture for relatively long period of time. Dexamethasone contributes to a better radial compression strength, while being located within the H-PLLA lm, probably due to its inherent stiffness.
The radial compression pressure needed to create a fracture in the L-PLLA stents is presented as a function of the immersion time in Fig. 10 . An almost linear decrease in the breaking pressure with an increase in the immersion time was obtained for all three stent types. The breaking pressures of the L-PLLA stents are higher than those of the L-PLLA/DM stents. Stents prepared from the A-type lm have a better resistance than those prepared from the B-type lm. The radial compression strength of the L-PLLA stents could be measured only for stents that were immersed for less than 10 weeks. Longer immersion times resulted in very brittle stents that could not be handled without breaking.
Interestingly, the H-PLLA/DM (B) lms can tolerate degradation with a minimal decrease in tensile mechanical properties (Fig. 3) . Moreover, H-PLLA/DM (B) stents are stronger than neat H-PLLA stents and retained a good radial compression strength throughout the 20-week study (Fig. 9) . In contrast, the L-PLLA/DM (B) stents showed the highest decrease in strength with time (Fig. 10 ). These differences result from their basic morphologies, as presented in Fig. 11 . While DM crystals are distributed throughout the whole cross-section of the H-PLLA/DM (B) lm, they are located mainly in the upper half of the L-PLLA/DM (B) lm. Hence, the effective DM content in certain domains of the L-PLLA/DM (B) lm is higher than the nominal one and enables the formation of a semi-network. DM was released from the sample probably due to the poor PLLA-DM interphase and therefore only the holes created can be observed. Therefore, it is suggested that the DM stiff molecules in the more homogenous H-PLLA/DM (B) lm contribute to better tolerability of degradation. The opposite trend, observed for the L-PLLA/DM (B) lms, is obtained due to the relatively poor dispersion of DM in L-PLLA. In summary, the mechanical properties of H-PLLA-based stents are better than those of L-PLLA ones. They combine high strength, which can be retained for relatively long periods of time, with good exibility. Incorporation of the steroidal drug DM on the surface of the H-PLLA lm (A-type) almost does not affect the stent's mechanical properties. The incorporation of DM in the lm (B-type) results in better mechanical properties. H-PLLA stents are therefore more applicable for supporting the trachea and were chosen for further studies. In contrast, L-PLLA stents can support the trachea for approximately 2 months. Although the radial compression pressure that they can endure is higher than the required value, their brittleness is not desired. The incorporation of DM in the lm reduces the mechanical properties of the L-PLLA stents.
The H-PLLA support structures were used in in vivo studies and tested for ef cacy as a stent in the trachea. Stents were implanted in rabbits and then followed by bronchoscopic examination of the rabbits at xed intervals. The bronchoscopic examination showed maintenance of airway patency throughout the experimental time period. Histology showed mild, but tolerable in ammation to the tracheal tissues. A large-scale study is currently underway and the results will be submitted for publication.
CONCLUSIONS
Bioresorbable PLLA lms containing dexamethasone (DM) were prepared through solution processing. In vitro studies of the lms focused on their mechanical properties in light of the morphology and degradation and erosion processes. Drug release from the lms was investigated. Novel expandable bioresorbable support devices (stents) developed from these lms were also studied.
In general, the PLLA lms showed good initial mechanical properties. The H-PLLA lm is stronger and more ductile than the L-PLLA lm. It can better accommodate drug incorporation on the lm surface and also in the bulk, due to its lower degree of crystallinity and ner spherulitic texture. Exposure of the lms to an aqueous medium resulted in a decrease in the tensile strength, modulus, and ductility due to chain scission and morphological changes. The H-PLLA lms underwent some degradation and small changes in morphology during the 20-week study and therefore retained good mechanical properties. In contrast, the L-PLLA lms lost weight and exhibited rough erosion features and a microporous structure in the interior. They therefore exhibited relatively fast deterioration in the mechanical properties. A linear release pro le of DM was obtained. The drug location / dispersion in the lm affected the release rate.
The H-PLLA tubular support structures developed from these lms demonstrated good mechanical properties. The stent radial compression strength is determined mainly by the polymer structure. Drug incorporation has a minor effect on the initial stent strength. While exposure to radial compression stress resulted in elastic reversible deformation of the H-PLLA stent, the L-PLLA stent exhibited a sudden brittle fracture. Incorporation of DM in the H-PLLA stents contributes to improved strength retention, due to its stiffness and good dispersion. Preliminary in vivo studies of these stents demonstrated excellent proof of principle and tolerable biocompatibility. Further animal studies are necessary. In general, H-PLLA stents are applicable for supporting various body conduits and were chosen for further studies.
